Guangdong Association Of Clinical Trials

This early study will test a personalized mRNA vaccine (RGL-270) given together with standard immunotherapy drugs in 40 people with advanced non-small cell lung cancer. The vaccine is custom-made to target unique markers on each person's tumor. The main goal is to check safety an…

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (detected by a blood test) after taking the drug osimertinib alone. The trial will test whether adding a second drug, sacituzumab tirumotecan, can improve out…

This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer changed from one type (EGFR-mutated non-small cell) to a more aggressive type (small-cell). About 66 adults aged 18-75 will take part. The goal is to see if the combo can slow can…

This study tests a combination of two drugs (IBI351 and cetuximab β) in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 48 participants will receive the treatment to see if it shrinks tumors and how safe it is. The goal i…

This study is for people with stage II-IIIB non-small cell lung cancer whose tumors did not fully disappear after initial chemotherapy plus immunotherapy. Researchers will use a blood test to look for tiny bits of cancer DNA (called MRD) to decide if additional immunotherapy with…